MiMedx Group, Inc
7.19+0.31 (+4.51%)
Oct 29, 4:00:02 PM EDT · NasdaqCM · MDXG · USD
Key Stats
Market Cap
1.06BP/E (TTM)
34.24Basic EPS (TTM)
0.21Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
MiMedx unveils growth updates
MiMedx Group updated its investor presentation ahead of the Cantor Global Healthcare Conference on September 3, 2025, highlighting robust growth in its wound care and surgical segments. Last twelve months sales in surgical rose 7% to $250,000 (000s), while wound care held steady at the same level, with surgical now comprising 35% of the mix. The company eyes further expansion through product innovations like EPIXPRESS and ongoing RCTs. Yet risks from reimbursement shifts loom large.
10-Q
Q2 FY2025 results
MiMedx posted Q2 net sales of $98.6M, up 13.1% y/y from $87.2M, with Wound up 12% to $64.5M and Surgical up 15.1% to $34.1M, yet operating income fell to $12.4M from $23.5M as SG&A climbed 15.8% on higher commissions and legal costs. Gross margin slipped to 81.1% from 83.0% due to production variances and product mix. Diluted EPS from continuing operations dropped to $0.06 from $0.12, aligning with 149.3M weighted shares. Cash swelled to $118.9M, up from $104.4M at year-end, with free cash flow of $19.2M (derived) from $19.7M operating cash minus $0.6M capex; total debt stands at $18.5M under the Citizens Term Loan at 6.7%, maturing 2029, and $75M revolver availability. The TELA deal, closed March 2024 for exclusive U.S. rights to a collagen product, carries $2.4M remaining profit share obligations. Sales grow steadily. Regulatory shifts in skin substitute payments loom as a reimbursement risk.
8-K
Record Q2 sales surge 13%
MiMedx Group reported record Q2 2025 net sales of $99 million, up 13% year-over-year, fueled by 12% wound growth from CELERA and EMERGE, and 15% surgical expansion via AMNIOFIX, AMNIOEFFECT, and HELIOGEN. Adjusted EBITDA hit $24 million, or 25% of sales, while cash swelled to $119 million. Medicare's proposed 2026 skin substitute reforms, capping prices at $125.38/cm² and demanding RCT data, favor MiMedx's proven portfolio amid curbing $10 billion in wasteful spending. Momentum builds for low double-digit full-year growth.
ENOV
Enovis Corporation
31.99-0.87
MD
Pediatrix Medical Group, Inc.
17.87+0.03
MDNC
MEDINOTEC INC
5.00+0.00
MDWD
MediWound Ltd.
18.07-0.20
OFIX
Orthofix Medical Inc.
15.32-0.70
OMI
Owens & Minor, Inc.
5.22-0.06
RMTG
Regenerative Medical Technology
0.05+0.00
SMTI
Sanara MedTech Inc.
29.44-0.91
TELA
TELA Bio, Inc.
1.32-0.12
TMDX
TransMedics Group, Inc.
134.32+4.61